Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
HiTek Global enters US$20 million deal to buy Beijing Fourth Coco owner Ju Fu Limited

HiTek Global enters US$20 million deal to buy Beijing Fourth Coco owner Ju Fu Limited

ReutersReuters2026/08/06 22:16
  • HiTek Global entered a share purchase agreement to buy Ju Fu Limited, owner of the Beijing Fourth Coco advertising and digital marketing business.
  • Purchase price set at USD 20 million, split between up to USD 14 million in cash and 4,000,000 Class A ordinary shares.
  • Cash includes USD 11 million due at two closings, with up to USD 3 million deferred based on performance targets.
  • Deal structured in two stages, with the first closing expected on or around Aug. 11, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HiTek Global Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-086241), on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Following Novartis, Novo Nordisk (NVO.US) terminates two cardiovascular clinical trials.

Novo Nordisk (NVO.US) has terminated two additional clinical trials of its experimental cardiovascular drug.

智通财经2026/09/07 11:21
Following Novartis, Novo Nordisk (NVO.US) terminates two cardiovascular clinical trials.